Abu Dhabi Biobank Collaborates with Japanese Firm on Stem Cell Innovations

Abu Dhabi Biobank has formed a pivotal partnership with the Japan-based Human Life CORD (HLC) to advance umbilical cord-derived stem cell therapies within Abu Dhabi. Supported by the Department of Health – Abu Dhabi (DoH) and the global health company M42, this initiative aims to enhance access to advanced stem cell treatments throughout the UAE and the broader Middle East and North Africa (MENA) region.

This collaboration signifies a significant advancement in establishing Abu Dhabi as a central hub for healthcare innovation, precision medicine, and life sciences. By merging Abu Dhabi Biobank's cutting-edge biobanking capacities with HLC's mesenchymal stem cell (MSC) technology, they will work to innovate targeted regenerative therapies that confront pressing health issues in the region.

Moreover, the Department of Health will promote public cord blood donations through the biobank, while overseeing operational standards to sustain high quality in research and innovation.

This initiative also marks the commencement of local manufacturing pathways for Umbilical Cord Mesenchymal Stem Cell (UC-MSC) therapies in the UAE, facilitating the entire treatment development process—from sample collection to clinical application—within the nation.

Globally, umbilical cord-derived therapies have garnered attention for their efficacy in inflammation reduction, tissue repair, and nerve cell protection. These therapies hold promise for treating ailments including diabetes, musculoskeletal issues, and age-related conditions, moving beyond mere symptom management.

Dr. Asma AlMannaei from the Department of Health remarked that this collaboration signifies a leap forward from standard cord blood donation to cutting-edge regenerative medicine, fostering preventive healthcare and elevating quality of life.

Paul Downey, the General Manager of Abu Dhabi Biobank, emphasized that this partnership intertwines quality biological data with practical treatment development, translating scientific discovery into viable medical solutions.

Masamitsu Harata, CEO of Human Life CORD, asserted that stem cell therapies have the potential to revolutionize chronic disease management. Collaborating with Abu Dhabi Biobank will facilitate patient access to groundbreaking treatments, leveraging local health data and production capabilities.

As a leader in this field, Human Life CORD has brought several stem cell therapies to advanced clinical phases in Japan.

This partnership aligns with Abu Dhabi's broader ambitions to enhance medical research and innovation, while also fortifying collaborative scientific efforts between the UAE and Japan.